On November 2, 2021 Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, reported the latest expansion of the Personalis NeXT Platform adding several new features that are key to the understanding of the interactions between the tumor and the immune system and how they may influence a cancer patient’s response to therapy (Press release, Personalis, NOV 2, 2021, View Source [SID1234594157]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The new and improved features include:
InfiltrateID, a sophisticated analytics module that leverages the augmented gene expression data from the NeXT Transcriptome to detect the presence of eight immune cell populations within a tumor sample
RepertoireID now incorporates the characterization of the B-cell receptor repertoire, including the computing of isotype makeup, as a complement to the previously released T-cell receptor repertoire feature
SHERPA, further enhancing the performance of Personalis’ leading pan-allelic neoantigen prediction algorithm recently published in the Immunopeptidomics Special Issue of the journal Molecular & Cellular Proteomics
Personalis CMO and SVP of R&D, Richard Chen, MD, said, "With the ability to identify immune cell populations in the tumor, characterize the B-cell and T-cell receptor repertoires, and better predict neoantigens, we are further expanding the NeXT Platform for additional emerging oncology biomarkers. As we recently demonstrated with our NEOPS biomarker publication, combining both tumor and immune features into a composite biomarker can lead to better stratification of patient response to cancer therapy. These new NeXT Platform features open up opportunities to further enhance composite biomarkers like NEOPS."
These advanced machine learning and algorithmic tools paired with the unique assay design of the NeXT Platform, further Personalis’ goal of providing the most comprehensive genomic tumor profiling platform available. The NeXT Platform consolidates multiple biomarker assays into one, enabling a seamless path from translational research to companion diagnostics development.